These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

682 related items for PubMed ID: 12953344

  • 1. Long-term changes in mycophenolic acid exposure in combination with tacrolimus and corticosteroids are dose dependent and not reflected by trough plasma concentration: a prospective study in 100 de novo renal allograft recipients.
    Kuypers DR, Claes K, Evenepoel P, Maes B, Coosemans W, Pirenne J, Vanrenterghem Y.
    J Clin Pharmacol; 2003 Aug; 43(8):866-80. PubMed ID: 12953344
    [Abstract] [Full Text] [Related]

  • 2. Time-related clinical determinants of long-term tacrolimus pharmacokinetics in combination therapy with mycophenolic acid and corticosteroids: a prospective study in one hundred de novo renal transplant recipients.
    Kuypers DR, Claes K, Evenepoel P, Maes B, Coosemans W, Pirenne J, Vanrenterghem Y.
    Clin Pharmacokinet; 2004 Aug; 43(11):741-62. PubMed ID: 15301578
    [Abstract] [Full Text] [Related]

  • 3. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
    Dösch AO, Ehlermann P, Koch A, Remppis A, Katus HA, Dengler TJ.
    Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
    [Abstract] [Full Text] [Related]

  • 4. Best single time points as surrogates to the tacrolimus and mycophenolic acid area under the curve in adult liver transplant patients beyond 12 months of transplantation.
    Mardigyan V, Tchervenkov J, Metrakos P, Barkun J, Deschenes M, Cantarovich M.
    Clin Ther; 2005 Apr; 27(4):463-9. PubMed ID: 15922819
    [Abstract] [Full Text] [Related]

  • 5. Best single time points to predict the area-under-the-curve in long-term heart transplant patients taking mycophenolate mofetil in combination with cyclosporine or tacrolimus.
    Mardigyan V, Giannetti N, Cecere R, Besner JG, Cantarovich M.
    J Heart Lung Transplant; 2005 Oct; 24(10):1614-8. PubMed ID: 16210138
    [Abstract] [Full Text] [Related]

  • 6. Pharmacokinetic basis for the efficient and safe use of low-dose mycophenolate mofetil in combination with tacrolimus in kidney transplantation.
    Mourad M, Malaise J, Chaib Eddour D, De Meyer M, König J, Schepers R, Squifflet JP, Wallemacq P.
    Clin Chem; 2001 Oct; 47(7):1241-8. PubMed ID: 11427455
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Mycophenolic acid 12-hour area under the curve in de novo liver transplant patients given mycophenolate mofetil at fixed versus concentration-controlled doses.
    Kamar N, Marquet P, Gandia P, Muscari F, Lavayssière L, Esposito L, Guitard J, Canivet C, Peron JM, Alric L, Suc B, Saint-Marcoux F, Rostaing L.
    Ther Drug Monit; 2009 Aug; 31(4):451-6. PubMed ID: 19531983
    [Abstract] [Full Text] [Related]

  • 9. Pharmacokinetics of mycophenolic acid in living donor liver transplantation.
    Shin M, Moon JI, Kim JM, Choi GS, Kwon CH, Kim SJ, Joh JW, Lee SK, Lee ST, Jung H, Lee SY.
    Transplant Proc; 2010 Apr; 42(3):846-53. PubMed ID: 20430188
    [Abstract] [Full Text] [Related]

  • 10. Defining algorithms for efficient therapeutic drug monitoring of mycophenolate mofetil in heart transplant recipients.
    Kaczmarek I, Bigdeli AK, Vogeser M, Mueller T, Beiras-Fernandez A, Kaczmarek P, Schmoeckel M, Meiser B, Reichart B, Ueberfuhr P.
    Ther Drug Monit; 2008 Aug; 30(4):419-27. PubMed ID: 18641552
    [Abstract] [Full Text] [Related]

  • 11. Abbreviated mycophenolic acid AUC from C0, C1, C2, and C4 is preferable in children after renal transplantation on mycophenolate mofetil and tacrolimus therapy.
    Filler G.
    Transpl Int; 2004 Mar; 17(3):120-5. PubMed ID: 14749919
    [Abstract] [Full Text] [Related]

  • 12. Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings.
    Zucker K, Rosen A, Tsaroucha A, de Faria L, Roth D, Ciancio G, Esquenazi V, Burke G, Tzakis A, Miller J.
    Transpl Immunol; 1997 Sep; 5(3):225-32. PubMed ID: 9402690
    [Abstract] [Full Text] [Related]

  • 13. Pharmacokinetics, efficacy, and safety of mycophenolate mofetil in combination with standard-dose or reduced-dose tacrolimus in liver transplant recipients.
    Nashan B, Saliba F, Durand F, Barcéna R, Herrero JI, Mentha G, Neuhaus P, Bowles M, Patch D, Bernardos A, Klempnauer J, Bouw R, Ives J, Mamelok R, McKay D, Truman M, Marotta P.
    Liver Transpl; 2009 Feb; 15(2):136-47. PubMed ID: 19177449
    [Abstract] [Full Text] [Related]

  • 14. The pharmacokinetics of mycophenolate mofetil in renal transplant recipients receiving standard-dose or low-dose cyclosporine, low-dose tacrolimus or low-dose sirolimus: the Symphony pharmacokinetic substudy.
    Grinyó JM, Ekberg H, Mamelok RD, Oppenheimer F, Sánchez-Plumed J, Gentil MA, Hernandez D, Kuypers DR, Brunet M.
    Nephrol Dial Transplant; 2009 Jul; 24(7):2269-76. PubMed ID: 19357111
    [Abstract] [Full Text] [Related]

  • 15. Pharmacokinetics and pharmacodynamics of mycophenolic acid in stable renal transplant recipients treated with low doses of mycophenolate mofetil.
    Brunet M, Martorell J, Oppenheimer F, Vilardell J, Millán O, Carrillo M, Rojo I, Corbella J.
    Transpl Int; 2000 Jul; 13 Suppl 1():S301-5. PubMed ID: 11112019
    [Abstract] [Full Text] [Related]

  • 16. Comparison of mycophenolic acid pharmacokinetic parameters in kidney transplant patients within the first 3 months post-transplant.
    Pawinski T, Durlik M, Szlaska I, Urbanowicz A, Majchrnak J, Gralak B.
    J Clin Pharm Ther; 2006 Feb; 31(1):27-34. PubMed ID: 16476117
    [Abstract] [Full Text] [Related]

  • 17. Correlation of mycophenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treated with mycophenolate mofetil.
    Mourad M, Malaise J, Chaib Eddour D, De Meyer M, König J, Schepers R, Squifflet JP, Wallemacq P.
    Clin Chem; 2001 Jan; 47(1):88-94. PubMed ID: 11148182
    [Abstract] [Full Text] [Related]

  • 18. Clinical efficacy and toxicity profile of tacrolimus and mycophenolic acid in relation to combined long-term pharmacokinetics in de novo renal allograft recipients.
    Kuypers DR, Claes K, Evenepoel P, Maes B, Vanrenterghem Y.
    Clin Pharmacol Ther; 2004 May; 75(5):434-47. PubMed ID: 15116056
    [Abstract] [Full Text] [Related]

  • 19. [Use of limited sampling strategy for estimating area under concentration-versus-time curve of mycophenolate sodium in renal allograft recipients].
    Yang SL, Gao X, Wang QH, Zhang J, Cai JQ, Guo JQ, Tang MY, Shang LL, Tan JM.
    Zhonghua Yi Xue Za Zhi; 2013 Dec 24; 93(48):3841-6. PubMed ID: 24548445
    [Abstract] [Full Text] [Related]

  • 20. Development and validation of limited sampling strategies for the estimation of mycophenolic acid area under the curve in adult kidney and liver transplant recipients receiving concomitant enteric-coated mycophenolate sodium and tacrolimus.
    Pawinski T, Luszczynska P, Durlik M, Majchrzak J, Baczkowska T, Chrzanowska M, Sobiak J, Glyda M, Kuriata-Kordek M, Kamińska D, Krajewska M, Klinger M.
    Ther Drug Monit; 2013 Dec 24; 35(6):760-9. PubMed ID: 24192641
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.